Expanded Access to NanoDoce

See also
Status	Clinical Trial	Phase
Completed	`NCT00377520` - A Trial for Patients With Advanced/Recurrent Endometrial Cancer	Phase 2
Recruiting	`NCT04462926` - Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed	N/A
Active, not recruiting	`NCT03344757` - Health Gatherings - For Your Health After Cancer	N/A
Recruiting	`NCT04566952` - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer	Phase 2
Completed	`NCT03562897` - Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer	Phase 2
Recruiting	`NCT04923178` - A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Terminated	`NCT02543645` - A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer	Phase 1
Terminated	`NCT04221828` - Trial of NanoPac Focal Therapy for Prostate Cancer	Phase 2
Not yet recruiting	`NCT05030077` - Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma	Phase 2
Recruiting	`NCT04556071` - Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	Phase 2
Completed	`NCT01523652` - Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients	N/A
Completed	`NCT04679675` - Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial	N/A
Terminated	`NCT02386111` - A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma	Phase 1
Completed	`NCT03081858` - Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer	Phase 1/Phase 2
Recruiting	`NCT04644432` - Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma	Phase 2
Recruiting	`NCT04811846` - CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood	N/A
Completed	`NCT04435964` - Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment
Recruiting	`NCT04922047` - Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)	Phase 1/Phase 2
Terminated	`NCT01918605` - Protection of Rectum From High Radiation Doses Using a Spacer	N/A
Completed	`NCT01316458` - Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy	Phase 2

NCT number	NCT04060628
Study type	Expanded Access
Source	NanOlogy, LLC
Contact	Gere diZerega, MD
Phone	805-595-1300
Email	gere.dizerega@usbiotest.com
Status	Available
Phase

Expanded Access to NanoDoce

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms